Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2019; 41(07): 440-448
DOI: 10.1055/s-0039-1693056
Original Article
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors

Tumores de células de Sertoli-Leydig ovarianos: fatores epidemiológicos, clínicos e prognósticos
Beatriz Guerreiro Ruiz Castro 
1   Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, SP, Brazil
,
Cristiano de Pádua Souza
2   Gynecologic Clinical Oncology Department, Hospital do Câncer de Barretos, Barretos, SP, Brazil
,
Carlos Eduardo Mattos da Cunha Andrade
3   Gynecologic Oncology Department, Hospital do Câncer de Barretos, Barretos, SP, Brazil
,
Marcelo de Andrade Vieira
3   Gynecologic Oncology Department, Hospital do Câncer de Barretos, Barretos, SP, Brazil
,
Diocésio Alves Pinto de Andrade
4   InORP ONCOCLÍNICAS Group (Instituto Oncológico de Ribeirão Preto), Ribeirão Preto, SP, Brazil
,
Ricardo dos Reis
3   Gynecologic Oncology Department, Hospital do Câncer de Barretos, Barretos, SP, Brazil
› Author Affiliations
Further Information

Publication History

05 February 2019

28 May 2019

Publication Date:
25 July 2019 (online)

   Permissions and Reprints

Abstract

Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs).

Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017.

Results The median age of the patients was 31 years old (15–71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138–569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1–11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0–2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7–3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1–147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2–23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred.

Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.

Resumo

Objetivo Descrever uma série de casos de tumores de células de Sertoli-Leydig (TCSLs) ovarianos.

Métodos Revisão retrospectiva de 12 casos de TCSL tratados no Hospital de Câncer de Barretos entre outubro de 2009 e agosto de 2017.

Resultados A mediana de idade foi 31 anos (15–71 anos). Um total de 9 pacientes (75,0%) apresentaram sintomas: 8 (66,7%) apresentaram dor abdominal, 5 (41,7%) apresentaram aumento abdominal, 2 (16,7%) apresentaram virilização, 2 (16,7%) apresentaram sangramento uterino anormal, 1 (8,3%) apresentou dispareunia, e 1 (8,3%) apresentou emagrecimento. A mediana de desidrogenase láctica (DHL) foi 504,5 U/L (138–569 U/L), alfafetoproteína (AFP) foi 2,0 ng/ml (1,1–11,3 ng/ml), gonadotrofina coriônica humana (β-hCG) foi 0,6 mUI/ml (0,0–2,3 mUI/ml), antígeno carcinoembrionário (CEA) foi 0,9 ng/ml (0,7–3,4) ng/ml, e antígeno cancerígeno 125 (CA-125) foi 26,0 U/ml (19,1–147,0 U/ml), todos pré-operatórios. Todos os tumores foram unilaterais e tratados cirurgicamente. Realizou-se linfadenectomia em 3 (25,0%) pacientes, porém, nenhuma das três apresentou acometimento linfonodal. No exame anatomopatológico, 1 tumor (8,3%) era bem diferenciado, 8 (66,7%) eram moderadamente diferenciados, e 3 (25,0%) eram pouco diferenciados. Um total de 5 (55,6%) tumores eram sólido-císticos, 2 (22,2%) eram puramente císticos, 1 (11,1%) era cístico com vegetações, e 1 (11,1%) era puramente sólido, mas para 3 pacientes estas informações não estavam disponíveis. A mediana da dimensão da lesão foi 14,2 cm (3,2–23,5 cm). Todos os tumores eram estádio IA de acordo com a classificação de 2014 da Federação Internacional de Ginecologia e Obstetrícia (FIGO, na sigla em inglês). Duas (16,7%) pacientes receberam adjuvância; uma realizou 3 ciclos de paclitaxel e carboplatina a cada 21 dias, e a outra 4 ciclos de ifosfamida, cisplatina e etoposide a cada 21 dias. Dentre todas as pacientes, nenhuma apresentou recidiva e houve um óbito relacionado a complicações após estadiamento cirúrgico.

Conclusão Dor abdominal foi a apresentação mais frequente. Todos os TCSLs eram estádio IA e a maioria era moderadamente diferenciada. Não ocorreram recidivas, mas ocorreu um óbito relacionado ao estadiamento cirúrgico.

Keywords

ovarian neoplasms - Sertoli-Leydig cell tumor - oncologic prognosis

Palavras-chave

neoplasias ovarianas - tumor de células de Sertoli-Leydig - prognóstico oncológico

Contributions

All of the authors contributed to the development of the present research, helped in the conception, the design, the data interpretation, and also in the critical review of the manuscript.


 

  • References

  • 1 Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H. Sertoli-Leydig cell tumor. Arch Gynecol Obstet 2001; 264 (04) 206-208 . Doi: 10.1007/s004040000114
    CrossrefPubMedGoogle Scholar
  • 2 Roth LM, Anderson MC, Govan AD, Langley FA, Gowing NF, Woodcock AS. Sertoli-Leydig cell tumors: a clinicopathologic study of 34 cases. Cancer 1981; 48 (01) 187-197 . Doi: 10.1002/1097-0142(19810701)48:1<187:AID-CNCR2820480130>3.0.CO;2-1
    CrossrefPubMedGoogle Scholar
  • 3 Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9 (08) 543-569 . Doi: 10.1097/00000478-198508000-00001
    CrossrefPubMedGoogle Scholar
  • 4 Gui T, Cao D, Shen K. , et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 2012; 127 (02) 384-389 . Doi: 10.1016/j.ygyno.2012.07.114
    CrossrefPubMedGoogle Scholar
  • 5 Akman L, Ertas IE, Gokcu M. , et al. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. J Cancer Res Ther 2016; 12 (01) 290-294 . Doi: 10.4103/0973-1482.158037
    CrossrefPubMedGoogle Scholar
  • 6 Bhat RA, Lim YK, Chia YN, Yam KL. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database. J Obstet Gynaecol Res 2013; 39 (01) 305-310 . Doi: 10.1111/j.1447-0756.2012.01928.x
    CrossrefPubMedGoogle Scholar
  • 7 Appetecchia M, Cela V, Bernardi F, Burelli A, Cionini R, Pucci E. Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservative surgery. Eur J Obstet Gynecol Reprod Biol 2004; 116 (01) 113-116 . Doi: 10.1016/j.ejogrb.2004.01.043
    CrossrefPubMedGoogle Scholar
  • 8 Xiao H, Li B, Zuo J. , et al. Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature. Gynecol Endocrinol 2013; 29 (03) 192-195 . Doi: 10.3109/09513590.2012.738723
    CrossrefPubMedGoogle Scholar
  • 9 Guo L, Yang X, Zhu H. , et al. Sertoli-Leydig cell tumor presenting hyperestrogenism in a postmenopausal woman: a case report and review of the literature. Taiwan J Obstet Gynecol 2012; 51 (04) 620-624 . Doi: 10.1016/j.tjog.2012.09.019
    CrossrefPubMedGoogle Scholar
  • 10 Tsuzuki Y, Kikuchi I, Nojima M, Yoshida K, Hashizume A, Tomita S. A case report: ovarian Sertoli-Leydig cell tumor with hyperestrogenism and endometrial hyperplasia in a postmenopausal woman. Jpn Clin Med 2017; 8: 1179066017695239 . Doi: 10.1177/1179066017695239
    CrossrefPubMedGoogle Scholar
  • 11 Sahoo TK, Kar T, Kar A, Panda S. Poorly differentiated Sertoli-Leydig cell tumour of ovary with heterologous elements. J Clin Diagn Res 2017; 11 (05) XD01-XD02 . Doi: 10.7860/JCDR/2017/25262.9860
    PubMedGoogle Scholar
  • 12 Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18 (Suppl. 02) S81-S98
    CrossrefPubMedGoogle Scholar
  • 13 Schneider DT, Orbach D, Cecchetto G. , et al. Ovarian Sertoli Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015; 51 (04) 543-550 . Doi: 10.1016/j.ejca.2014.11.013
    CrossrefPubMedGoogle Scholar
  • 14 Sigismondi C, Gadducci A, Lorusso D. , et al. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. Gynecol Oncol 2012; 125 (03) 673-676 . Doi: 10.1016/j.ygyno.2012.03.024
    CrossrefPubMedGoogle Scholar
  • 15 Nam SM, Kim JW, Eoh KJ. , et al. A novel clinicopathological analysis of early stage ovarian Sertoli-Leydig cell tumors at a single institution. Obstet Gynecol Sci 2017; 60 (01) 39-45 . Doi: 10.5468/ogs.2017.60.1.39
    CrossrefPubMedGoogle Scholar
  • 16 Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?. Gynecol Oncol 2009; 113 (01) 86-90 . Doi: 10.1016/j.ygyno.2008.12.007
    CrossrefPubMedGoogle Scholar
  • 17 Thrall MM, Paley P, Pizer E, Garcia R, Goff BA. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol 2011; 122 (02) 242-245 . Doi: 10.1016/j.ygyno.2011.03.020
    CrossrefPubMedGoogle Scholar
  • 18 Prat J. ; FIGO Committee on Gynecologic Oncology. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 2015; 26 (02) 87-89 . Doi: 10.3802/jgo.2015.26.2.87
    CrossrefPubMedGoogle Scholar
  • 19 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381 . Doi: 10.1016/j.jbi.2008.08.010
    CrossrefPubMedGoogle Scholar
  • 20 Chi M, Gilman AD, Iroegbu N. Management of metastatic ovarian Sertoli-Leydig cell tumor with sporadic multinodular goiter: a case report and literature review. Future Oncol 2011; 7 (09) 1113-1117 . Doi: 10.2217/fon.11.89
    CrossrefPubMedGoogle Scholar
  • 21 Zhang HY, Zhu JE, Huang W, Zhu J. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors. Int J Clin Exp Pathol 2014; 7 (10) 6956-6964
    PubMedGoogle Scholar
  • 22 Watanabe T, Yamada H, Morimura Y, Abe M, Motoyama T, Sato A. Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report. J Obstet Gynaecol Res 2008; 34 (03) 418-421 . Doi: 10.1111/j.1447-0756.2008.00730.x
    CrossrefPubMedGoogle Scholar
  • 23 Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J Clin Oncol 2007; 25 (20) 2944-2951 . Doi: 10.1200/JCO.2007.11.1005
    CrossrefPubMedGoogle Scholar